



07-05-02

RECEIVED
AUG 1 2002

Gp # 1615

TECH CENTER 1600/2000
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Approved for use through 04/30/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

Complete if Known 09/835,501

Application Number	09/835,501
Filing Date	09/16/2001
First Named Inventor	Tyler Parr, Ph.D.
Examiner Name	Robert M Joynes
Group Art Unit	1615
Attorney Docket No.	

AC
8/20/02
JUL 11 2002

RECEIVED

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

Deposit Account:

Deposit Account Number
Deposit Account Name

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	\$180
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid


SUBTOTAL (3) (\$ 180)

SUBMITTED BY

Name (Print/Type)	Tyler Parr, Ph.D.	Registration No. (Attorney/Agent)		Telephone (323) 865-0506
Signature	Ty Parr		Date 29 Jun 02	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
AUG 21 2002
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	09/853,501
Filing Date	04/16/2001
First Named Inventor	Tyler Perrin, Ph.D.
Group Art Unit	1615
Examiner Name	Robert M. Joyner
Attorney Docket Number	

JUL 11 2002

RECEIVED
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		1. Kojima M., Hosoda H., Date Y., Makazato M., Matsuo H., Kangawa K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide ... Nature 402:656-660	
		2. van Coevorden A., Mockel J., Laurent E., Kerckhofs M., L'Hermitte-Baleriaux M., Decoster C., Neve P., van Cauter E. (1991) Neuroendocrine rhythms and sleep in aging men. Am J Physiol 260:E651-E661	
		3. Mendelson W.B., Lantigua R.A., Wyatt R.J., Gillin C., Jacobs L.S. (1981) Piperidine Enhances Sleep-Related and Insulin-Induced Growth Hormone Secretion. J.Clin.Endocrinol.Metab.52:409-415	
		4. van Cauter E., FW Turek 1995 Endocrine and Other Biological Rhythms. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol 3. W. B. Saunders Co., Philadelphia, pp 2487-2548	
		5. Muller EE 1995 Role of Neurotransmitters and Neuromodulators in the Control of Anterior Pituitary Hormone Secretion. In: DeGroot LJ (eds) Endocrinology, 3rd Edition, Vol.1, pp 178-191	
		6. Wass JA, M Besser 1995 Tests of Pituitary Function. In: DeGroot LJ (eds) Endocrinology 3rd Ed. Vol. 1. W.B. Saunders Co., Philadelphia, pp 487-496	
		7. Parker M.L., hammond J.M., Daughaday W.H. (1967) The Arginine Provocative Test: An Aid in the Diagnosis of Hyposomatotropism. J Clin Endocrinol.Metab.27:1129-1136	
		8. Corpas E., Blackman M.R., Robertson R., Scholfield D., Harman S.M. (1993) Oral Arginine-Lysine Does not Increase Growth Hormone or Insulin-like Growth Factor-I in Old Men. J Gerontol.48:M128-M133	T ¹
		9. Chin M.-Y., Kreutzer R.A. (1992) Acute Poisoning from g-Hydroxybutyrate in California. W J Med 156:380-384	370
		10. Parr T. (1996) Insulin Exposure Controls the Rate of Mammalian Aging. Mech Ageing Dev 88:75-82	MAIL JUL 16 2002
		11. Parr T. (1997) Insulin Exposure and Aging Theory. Gerontology 43:182-200	2000

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

AUG 21 2002

TECH CENTER 1600/2000
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	09/853,501
Filing Date	04/16/2001
First Named Inventor	Tyler Parr
Group Art Unit	5615
Examiner Name	Robert M. Jaynes
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the publication, name and address of publisher, city and/or country where published	T ²
		12. Rambok (1999) Inulin, Exports and, Unifying Aging gerontology 45:121-135 number(s), publisher, city and/or country where published	
		13. Parr T.B. (2001) A New Technique to Elevate of Night Time Growth Hormone Release and a Potential Growth Hormone Feedback Control Loop. Med Hypotheses 56:610-613	
		14. Paradies G., Ruggiero F.M., Petrosillo G., Gadaleta M.N., Quagliariello E. (1994) The Effect of Aging and Acetyl-L-carnitine on the Function and on the Lipid Composition.... Ann. N. Y. Acad. Sci. 717: 233-243	
		15. Buttigereit F., Brand M.D. (1995) A hierarchy of ATP-consuming processes in mammalian cells...Biochem.J.312:163-167	
		16. Castorina M., Ferraris L. (1994) Acetyl-L-carnitine affects aged brain receptor system in rodents. Life Sci 54:1205-1214	
		17. Ranke MB 1995 Growth Hormone Insufficiency: Clinical Features, Diagnosis, and Therapy. In: DeGroot LJ (eds) Endocrinology 3 rd Ed.. W. B. Saunders Co., Philadelphia, pp	1 31/00
		18. Basset A., Bonardet A., Roundouin G., Descomps B., Passouant P. (1982) Increase in sleep related GH and PRL secretion after chronic agrinine aspartate administration in man. Acta Endocrinol 99:18-23	JUL 16 2002 MAIL
		19. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Cornelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Salsi A., Calogero P., Parma E., Stramba-Bidale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzzi M., Favaretto M., Bozeglav C., Alberoni M., Ed Leo D., Serraiotto L., Baiocchi A., Sciccia S., Culotta P., Ieracitano D. (1991) Long -term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41:1726-1732	000
		20. Bowman B.A. (1992) Acetyl-carnitine and Alzheimer's disease. Nutr Rev 50:142-144	
		21. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., McClure R.J. (1995) Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 16:1-4	
		22. Goa K.L., Brogden R.N. (1987) L-Carnitine A Preliminary Review of its Pharmacokinetics, and its Therapeutic use in Ischemic Cardiac Diseases and Primary and Secondary Carnitine Deficiencies.... Drugs 34:1-24	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

TECH CENTER 1600/2000
JUL 11 2002

